How to buy Reata Pharmaceuticals stock (RETA)

Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 321 staff and has a trailing 12-month revenue of around $23.5 million.

Our top picks for where to buy Reata Pharmaceuticals stock

Buy Reata Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Reata Pharmaceuticals stock price (NASDAQ: RETA)

Use our graph to track the performance of RETA stocks over time.

Reata Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$160.97
200-day moving average more info button	$97.64
Wall St. target price	$172.40
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-2.60

Is it a good time to buy Reata Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Reata Pharmaceuticals financials

Revenue TTM	$23.5 million
Gross profit TTM	$-167,627,000
Return on assets TTM	-37.66%
Return on equity TTM	-112.39%
Profit margin	0%
Book value	$2.31
Market Capitalization more info button	$6.6 billion

TTM: trailing 12 months

Reata Pharmaceuticals share dividends

We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.

Reata Pharmaceuticals share price volatility

Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.4194. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Reata Pharmaceuticals overview

Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc.

Frequently asked questions

What percentage of Reata Pharmaceuticals is owned by insiders or institutions?
Currently 4.101% of Reata Pharmaceuticals shares are held by insiders and 88.465% by institutions. How many people work for Reata Pharmaceuticals?
Latest data suggests 321 work at Reata Pharmaceuticals. When does the fiscal year end for Reata Pharmaceuticals?
Reata Pharmaceuticals's fiscal year ends in December. Where is Reata Pharmaceuticals based?
Reata Pharmaceuticals's address is: 5320 Legacy Drive, Plano, TX, United States, 75024 What is Reata Pharmaceuticals's ISIN number?
Reata Pharmaceuticals's international securities identification number is: US75615P1030 What is Reata Pharmaceuticals's CUSIP number?
Reata Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75615P103